Vertex and crispr therapeutics announce licensing agreement to accelerate development of vertex's hypoimmune cell therapies for the treatment of type 1 diabetes

Boston & zug, switzerland--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) and crispr therapeutics (nasdaq: crsp) today announced that they have entered into a new non-exclusive licensing agreement for the use of crispr therapeutics' gene editing technology, known as crispr/cas9, to accelerate the development of vertex's hypoimmune cell therapies for type 1 diabetes (t1d).
VRTX Ratings Summary
VRTX Quant Ranking